MedTrace Logo

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-09

No results posted yet for this study

Summary

This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

Conditions

  • Atypical Alzheimer's Disease
  • Logopenic Progressive Aphasia (LPA)
  • Posterior Cortical Atrophy (PCA)
  • Alzheimer Disease
  • Alzheimer Disease, Early Onset
  • Amnestic Disorder
  • Amnestic Symptoms
  • Amnestic Mild Cognitive Disorder

Interventions

DRUG

F-18 AV 1451

Tau binding agent

DRUG

C-11 PiB

Amyloid binding agent

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Jennifer Whitwell, Ph.D. · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02740634 on ClinicalTrials.gov